Financial Ratios Hansoh Pharmaceutical Group Company Limited
Equities
3692
KYG549581067
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.16 HKD | -1.51% |
|
-2.98% | -2.55% |
| 05-14 | Hansoh Pharma Gets China Nod for Trial of Tumor Drug | MT |
| 05-13 | Hansoh pharmaceutical says HS-10541 tablets obtain clinical trial approval from China's NMPA | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.55 | 5.7 | 5.31 | 7.54 | 9.44 | |||||
Return on Total Capital | 8.66 | 6.41 | 5.86 | 8.28 | 10.51 | |||||
Return On Equity % | 14.31 | 12.11 | 13.53 | 16.05 | 17.35 | |||||
Return on Common Equity | 14.31 | 12.11 | 13.53 | 16.05 | 17.35 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 91.24 | 90.73 | 89.78 | 90.89 | 89.89 | |||||
SG&A Margin | 44 | 44.21 | 41.97 | 36.77 | 31.51 | |||||
EBITDA Margin % | 31.74 | 31.25 | 29.94 | 34.89 | 38.37 | |||||
EBITA Margin % | 29.15 | 27.89 | 26.62 | 31.93 | 36.03 | |||||
EBIT Margin % | 29.15 | 27.79 | 26.52 | 31.83 | 35.94 | |||||
Income From Continuing Operations Margin % | 27.31 | 27.54 | 32.44 | 35.66 | 36.97 | |||||
Net Income Margin % | 27.31 | 27.54 | 32.44 | 35.66 | 36.97 | |||||
Net Avail. For Common Margin % | 27.31 | 27.54 | 32.44 | 35.66 | 36.97 | |||||
Normalized Net Income Margin | 19.83 | 20.18 | 23.14 | 25.74 | 27.29 | |||||
Levered Free Cash Flow Margin | 13.12 | 15.48 | 20.48 | 19.58 | 34.35 | |||||
Unlevered Free Cash Flow Margin | 13.45 | 15.87 | 20.89 | 19.61 | 34.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.41 | 0.33 | 0.32 | 0.38 | 0.42 | |||||
Fixed Assets Turnover | 3.44 | 2.71 | 3 | 3.76 | 4.68 | |||||
Receivables Turnover (Average Receivables) | 2.92 | 2.59 | 2.97 | 3.84 | 4.82 | |||||
Inventory Turnover (Average Inventory) | 2.46 | 2.03 | 2.02 | 1.82 | 2.41 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.67 | 9.86 | 4.21 | 10.18 | 8.09 | |||||
Quick Ratio | 7.52 | 9.64 | 4.11 | 9.9 | 7.92 | |||||
Operating Cash Flow to Current Liabilities | 0.85 | 1.05 | 0.45 | 1.43 | 1.53 | |||||
Days Sales Outstanding (Average Receivables) | 124.97 | 141.11 | 122.69 | 95.29 | 75.66 | |||||
Days Outstanding Inventory (Average Inventory) | 148.63 | 179.95 | 180.94 | 201.08 | 151.38 | |||||
Average Days Payable Outstanding | 69.28 | 94.6 | 60.72 | 58.58 | 68.23 | |||||
Cash Conversion Cycle (Average Days) | 204.32 | 226.46 | 242.91 | 237.78 | 158.81 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 19.11 | 19.33 | 16.68 | 0.41 | 0.3 | |||||
Total Debt / Total Capital | 16.05 | 16.2 | 14.3 | 0.41 | 0.3 | |||||
LT Debt/Equity | 19.06 | 19.26 | 0.4 | 0.21 | 0.13 | |||||
Long-Term Debt / Total Capital | 16 | 16.14 | 0.35 | 0.21 | 0.13 | |||||
Total Liabilities / Total Assets | 26.26 | 24.51 | 21.93 | 9.41 | 11.37 | |||||
EBIT / Interest Expense | 54.84 | 44.85 | 40.18 | 583.36 | 1.71K | |||||
EBITDA / Interest Expense | 59.99 | 50.77 | 45.68 | 643.36 | 1.83K | |||||
(EBITDA - Capex) / Interest Expense | 51.28 | 46.08 | 42.38 | 610.18 | 1.72K | |||||
Total Debt / EBITDA | 1.21 | 1.48 | 1.41 | 0.03 | 0.02 | |||||
Net Debt / EBITDA | -4.77 | -5.84 | -6.76 | -5.41 | -5.43 | |||||
Total Debt / (EBITDA - Capex) | 1.41 | 1.63 | 1.52 | 0.03 | 0.02 | |||||
Net Debt / (EBITDA - Capex) | -5.58 | -6.44 | -7.28 | -5.71 | -5.79 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.33 | -5.56 | 7.69 | 21.35 | 22.57 | |||||
Gross Profit, 1 Yr. Growth % | 14.94 | -6.1 | 6.57 | 22.85 | 21.22 | |||||
EBITDA, 1 Yr. Growth % | 5.5 | -4.93 | 3.18 | 41.41 | 34.78 | |||||
EBITA, 1 Yr. Growth % | 4.46 | -7.45 | 2.82 | 45.55 | 38.29 | |||||
EBIT, 1 Yr. Growth % | 4.46 | -7.56 | 2.76 | 45.64 | 38.42 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 5.61 | -4.76 | 26.85 | 33.39 | 27.07 | |||||
Net Income, 1 Yr. Growth % | 5.61 | -4.76 | 26.85 | 33.39 | 27.07 | |||||
Normalized Net Income, 1 Yr. Growth % | 4.73 | -3.9 | 23.5 | 35.01 | 29.96 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 1.21 | -1.29 | 19.65 | 40.62 | 26.42 | |||||
Accounts Receivable, 1 Yr. Growth % | 17.54 | -2.66 | -10.18 | -1.38 | -3.45 | |||||
Inventory, 1 Yr. Growth % | 37.29 | 9.21 | 28.55 | 13.1 | -6.5 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 50.85 | -0.73 | -4.93 | -0.99 | -2.09 | |||||
Total Assets, 1 Yr. Growth % | 30.63 | 10.46 | 10.12 | -4.18 | 26.04 | |||||
Tangible Book Value, 1 Yr. Growth % | 12.01 | 13 | 13.28 | 11 | 23.1 | |||||
Common Equity, 1 Yr. Growth % | 12.05 | 13.07 | 13.9 | 11.18 | 23.31 | |||||
Cash From Operations, 1 Yr. Growth % | 7.81 | 6.37 | 13.69 | 23.93 | 74.46 | |||||
Capital Expenditures, 1 Yr. Growth % | -67.78 | -40.7 | -19.51 | 1.08 | 60.58 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -135.47 | 15.68 | 42.45 | 16.01 | 115.01 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -136.38 | 15.53 | 41.77 | 13.92 | 114.72 | |||||
Dividend Per Share, 1 Yr. Growth % | 12.44 | 20.84 | 118.47 | 63.53 | 22.73 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.97 | 3.91 | 0.85 | 14.31 | 21.96 | |||||
Gross Profit, 2 Yr. CAGR % | 6.81 | 3.89 | 0.04 | 14.42 | 22.03 | |||||
EBITDA, 2 Yr. CAGR % | 3.15 | -0.96 | -0.96 | 20.79 | 38.06 | |||||
EBITA, 2 Yr. CAGR % | 2.07 | -2.86 | -2.45 | 22.33 | 41.87 | |||||
EBIT, 2 Yr. CAGR % | 2.07 | -3.03 | -2.54 | 22.33 | 41.98 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 3.01 | 0.29 | 9.91 | 30.08 | 30.19 | |||||
Net Income, 2 Yr. CAGR % | 3.01 | 0.29 | 9.91 | 30.08 | 30.19 | |||||
Normalized Net Income, 2 Yr. CAGR % | 2.86 | 0.32 | 8.94 | 29.13 | 32.46 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -2.64 | -0.05 | 8.68 | 29.71 | 33.33 | |||||
Accounts Receivable, 2 Yr. CAGR % | 27.93 | 6.97 | -6.49 | -5.88 | -2.42 | |||||
Inventory, 2 Yr. CAGR % | -0.51 | 22.45 | 18.49 | 20.58 | 2.84 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 34.26 | 22.37 | -2.86 | -2.98 | -1.54 | |||||
Total Assets, 2 Yr. CAGR % | 17.79 | 20.12 | 10.29 | 2.72 | 9.89 | |||||
Tangible Book Value, 2 Yr. CAGR % | 23.88 | 12.51 | 13.14 | 12.13 | 16.89 | |||||
Common Equity, 2 Yr. CAGR % | 23.91 | 12.56 | 13.48 | 12.53 | 17.09 | |||||
Cash From Operations, 2 Yr. CAGR % | -12.02 | 7.08 | 9.97 | 18.7 | 47.04 | |||||
Capital Expenditures, 2 Yr. CAGR % | -11.88 | -56.29 | -30.91 | -9.8 | 27.4 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -38.21 | -37.12 | 28.37 | 28.55 | 57.94 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -37.43 | -36.33 | 27.98 | 27.09 | 56.4 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | 16.57 | 62.48 | 89.01 | 41.67 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.76 | 2.62 | 5.15 | 7.26 | 17 | |||||
Gross Profit, 3 Yr. CAGR % | 8.39 | 2.32 | 4.77 | 7.13 | 16.64 | |||||
EBITDA, 3 Yr. CAGR % | 9.72 | -0.36 | 0.4 | 11.52 | 25.29 | |||||
EBITA, 3 Yr. CAGR % | 8.96 | -2.01 | -1.01 | 11.47 | 27.44 | |||||
EBIT, 3 Yr. CAGR % | 8.96 | -2.12 | -1.14 | 11.43 | 27.48 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 12.55 | 0.35 | 8.46 | 17.24 | 29.07 | |||||
Net Income, 3 Yr. CAGR % | 12.55 | 0.35 | 8.46 | 17.24 | 29.07 | |||||
Normalized Net Income, 3 Yr. CAGR % | 11.42 | 0.55 | 7.52 | 17.02 | 29.4 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 5.15 | -2.19 | 6.13 | 18.43 | 28.61 | |||||
Accounts Receivable, 3 Yr. CAGR % | 11.59 | 16.8 | 0.92 | -4.82 | -5.08 | |||||
Inventory, 3 Yr. CAGR % | -5.09 | 2.63 | 24.45 | 16.66 | 10.78 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 35.99 | 21.41 | 12.49 | -2.24 | -2.69 | |||||
Total Assets, 3 Yr. CAGR % | 47.79 | 15.3 | 16.69 | 5.24 | 9.97 | |||||
Tangible Book Value, 3 Yr. CAGR % | 101.19 | 20.14 | 12.76 | 12.42 | 15.68 | |||||
Common Equity, 3 Yr. CAGR % | 100.96 | 20.19 | 13 | 12.71 | 16.02 | |||||
Cash From Operations, 3 Yr. CAGR % | 7.54 | -6.28 | 9.24 | 14.44 | 34.96 | |||||
Capital Expenditures, 3 Yr. CAGR % | 6.45 | -22.78 | -46.42 | -21.57 | 9.32 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -30.84 | -24.78 | -17.42 | 24.11 | 52.6 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -30.26 | -24.16 | -16.86 | 23.11 | 51.36 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | 43.72 | 62.83 | 63.67 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.83 | 8.69 | 5.52 | 7.15 | 11.58 | |||||
Gross Profit, 5 Yr. CAGR % | 12.48 | 8.24 | 4.97 | 7 | 11.36 | |||||
EBITDA, 5 Yr. CAGR % | 11.48 | 8.3 | 4.85 | 7.61 | 14.04 | |||||
EBITA, 5 Yr. CAGR % | 11.03 | 7.33 | 3.74 | 7.09 | 14.32 | |||||
EBIT, 5 Yr. CAGR % | 11.03 | 7.26 | 3.66 | 7.01 | 14.26 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 12.95 | 10.12 | 11.49 | 11.33 | 16.68 | |||||
Net Income, 5 Yr. CAGR % | 12.95 | 10.12 | 11.49 | 11.33 | 16.68 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.9 | 9.5 | 10.42 | 11.13 | 16.88 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | 6.55 | 9.5 | 16.27 | |||||
Accounts Receivable, 5 Yr. CAGR % | 16.36 | 10.29 | 3.97 | 7.13 | -0.43 | |||||
Inventory, 5 Yr. CAGR % | 3.04 | 0.39 | 3.72 | 9.46 | 15.31 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 27.09 | 24.11 | 18.87 | 10.99 | 6.65 | |||||
Total Assets, 5 Yr. CAGR % | 41.31 | 38.56 | 31.46 | 10.09 | 13.92 | |||||
Tangible Book Value, 5 Yr. CAGR % | 46.47 | 38.05 | 59.81 | 16.87 | 14.4 | |||||
Common Equity, 5 Yr. CAGR % | 46.44 | 38.04 | 59.9 | 17.07 | 14.62 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.63 | 14.35 | 8.5 | 3.01 | 23.03 | |||||
Capital Expenditures, 5 Yr. CAGR % | 14 | 1.25 | -10.45 | -17.83 | -24.23 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 62.75 | -12.08 | -6.8 | 7.04 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 63.56 | -11.73 | -6.76 | 7.05 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | - | 42.89 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















